On May 31, 2023, the California Institute for Regenerative Medicine (CIRM) awarded $10 million to five facilities as part of the first phase to build a California Cell and Gene Therapy Manufacturing Network.

The statewide network is designed to overcome manufacturing bottlenecks that have delayed or stalled development and approval of regenerative medicines.

Phase one of the awards will fund California non-profit GMP manufacturing facilities for two years. Each facility will support in accelerating and de-risking the path to commercialization for cell and gene therapies, advancing industry standards and quality by design, and building a diverse and highly skilled manufacturing workforce in California.  

Phase two of the awards will fund collaborative partnerships that will scale efforts from the first phase across the network. 

The clinical award is part of CIRM’s CLIN2 awards, which support with the completion of a clinical trial for a regenerative medicine-based therapy (stem cell-based or gene therapy) that addresses an unmet medical need.  This award brings the total of CIRM-funded clinical trials to 91.